Adding Helper Peptide to Cancer Vaccine Supercharges Immune Response in Brain Tumor Patients
Combining a WT1 helper peptide with a WT1 killer T cell peptide vaccine produced stronger, more durable anti-tumor immune responses in glioma patients by generating a novel long-lived CD5-high killer T cell population.
Quick Facts
What This Study Found
WT1 CTL + helper peptide vaccine induced stronger WT1-specific CTL responses than CTL peptide alone in glioma patients, generating a novel WT1-tetramer-high CD5-high CTL population with enhanced persistence capacity.
Key Numbers
Two CTL populations; CD5-low (WT1-tetramer-low) and CD5-high (WT1-tetramer-high); CD5-high resistant to AICD; CTL-HTL response correlation; helper peptide enhanced CTL induction
How They Did This
Clinical immunological study in patients with recurrent glioma. Compared WT1 CTL peptide alone versus WT1 CTL + WT1 helper peptide (WT1332) vaccination. T cell responses measured by tetramer staining, TCR expression, CD5 levels, and proliferation assays.
Why This Research Matters
Glioma (brain cancer) has very poor outcomes. This study shows that adding a helper peptide to cancer vaccines can dramatically improve immune responses, potentially improving survival — a principle applicable to many peptide-based cancer vaccines.
The Bigger Picture
This study demonstrates a key principle in cancer immunotherapy: killer T cells need helper T cell support to mount optimal responses. Helper peptides that boost this cooperation could improve many existing and future peptide cancer vaccines across tumor types.
What This Study Doesn't Tell Us
Small clinical study in recurrent glioma patients. Immunological endpoints only — clinical survival benefit not directly demonstrated. Results may be specific to WT1 and this HLA context.
Questions This Raises
- ?Does the improved immune response translate to longer survival in glioma patients?
- ?Can the CD5-high CTL population approach be applied to other cancer peptide vaccines?
- ?Would this helper peptide strategy work in combination with checkpoint inhibitors?
Trust & Context
- Key Stat:
- Novel CD5-high killer T cells The helper peptide vaccine generated a new population of killer T cells with high CD5 expression, making them resistant to self-destruction and able to persist long-term
- Evidence Grade:
- Moderate evidence: clinical immunological data from glioma patients showing clear immune enhancement, but small study without survival outcome data.
- Study Age:
- Published 2021. WT1 peptide vaccines continue in clinical development for multiple cancer types.
- Original Title:
- Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
- Published In:
- Cancer immunology, immunotherapy : CII, 70(1), 253-263 (2021)
- Authors:
- Fujiki, Fumihiro(3), Tsuboi, Akihiro(3), Morimoto, Soyoko(3), Hashimoto, Naoya, Inatome, Miki, Nakajima, Hiroko, Nakata, Jun, Nishida, Sumiyuki, Hasegawa, Kana, Hosen, Naoki, Oka, Yoshihiro, Oji, Yusuke, Sogo, Shinji, Sugiyama, Haruo
- Database ID:
- RPEP-05394
Evidence Hierarchy
Frequently Asked Questions
What is a WT1 peptide vaccine?
WT1 is a protein found on many cancer cells. A WT1 peptide vaccine contains short fragments of this protein that train the immune system to recognize and attack cancer cells displaying WT1. Adding a helper peptide boosts this immune training.
Why are helper peptides important for cancer vaccines?
Killer T cells (which destroy cancer) need support from helper T cells to mount a full immune response. Helper peptides activate these support cells, leading to stronger, more durable anti-cancer immunity than killer peptide vaccines alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05394APA
Fujiki, Fumihiro; Tsuboi, Akihiro; Morimoto, Soyoko; Hashimoto, Naoya; Inatome, Miki; Nakajima, Hiroko; Nakata, Jun; Nishida, Sumiyuki; Hasegawa, Kana; Hosen, Naoki; Oka, Yoshihiro; Oji, Yusuke; Sogo, Shinji; Sugiyama, Haruo. (2021). Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.. Cancer immunology, immunotherapy : CII, 70(1), 253-263. https://doi.org/10.1007/s00262-020-02675-9
MLA
Fujiki, Fumihiro, et al. "Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.." Cancer immunology, 2021. https://doi.org/10.1007/s00262-020-02675-9
RethinkPeptides
RethinkPeptides Research Database. "Identification of two distinct populations of WT1-specific c..." RPEP-05394. Retrieved from https://rethinkpeptides.com/research/fujiki-2021-identification-of-two-distinct
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.